Hospital
Tarpon Springs Hospital Foundation INC
Tarpon Springs Hospital Foundation INC was paid $6.03M by Medicaid between Jan 2018 and Nov 2024, across 122 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoTARPON SPRINGS HOSPITAL FOUNDATION INC
TARPON SPRINGS, FL 34689
TARPON SPRINGS, FL 34689
33aNPI1568473015assigned 08/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.03M
24GClaims251,430
24DCodes billed122
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#74 of 163
Median peer was paid$4.77M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,406 | $213K | |
| 2019 | 55,518 | $1.41M | |
| 2020 | 39,916 | $916K | |
| 2021 | 52,768 | $1.16M | |
| 2022 | 50,676 | $1.23M | |
| 2023 | 27,224 | $843K | |
| 2024incomplete | 4,922 | $258K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 15,743 | 13,663 | $1.17M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 12,793 | 10,405 | $804K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 10% | 17,408 | 4,101 | $612K |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.9% | 4,475 | 3,482 | $414K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4.6% | 2,805 | 2,273 | $275K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.2% | 5,367 | 4,256 | $255K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 1,851 | 1,530 | $236K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.8% | 2,998 | 2,273 | $229K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 3.3% | 1,449 | 1,173 | $198K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.1% | 2,850 | 2,538 | $190K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.7% | 4,877 | 1,494 | $163K |
| 97161 | 2.5% | 1,433 | 1,312 | $150K |
110 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 2.2% | 4,843 | $134K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.6% | 11,798 | $98K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 2,835 | $85K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.4% | 4,869 | $83K |
| 82947 | 1.4% | 3,661 | $82K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.2% | 9,282 | $72K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,633 | $60K |
| 97162 | <1% | 759 | $59K | |
| 80053 | Comprehensive metabolic panel | <1% | 13,014 | $53K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,118 | $53K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,055 | $47K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 412 | $36K |
| 81025 | <1% | 3,717 | $35K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 460 | $26K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 901 | $26K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,816 | $25K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 992 | $25K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 667 | $24K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,419 | $23K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 282 | $21K |
| 87070 | <1% | 1,144 | $20K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,429 | $20K |
| 81001 | <1% | 5,475 | $18K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,067 | $13K |
| 73610 | <1% | 264 | $13K | |
| 81003 | <1% | 2,704 | $12K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,101 | $12K |
| G0378 | Hospital observation service, per hour | <1% | 2,468 | $11K |
| 96376 | <1% | 1,454 | $11K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,395 | $10K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,633 | $8K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 385 | $8K |
| 87430 | <1% | 1,163 | $8K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 14 | $7K |
| 84484 | <1% | 6,054 | $7K | |
| 73630 | <1% | 195 | $6K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,394 | $6K |
| 73562 | <1% | 252 | $6K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,581 | $5K |
| 84702 | <1% | 943 | $5K | |
| 73130 | <1% | 80 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,043 | $4K |
| 83880 | <1% | 739 | $4K | |
| 73030 | <1% | 75 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,421 | $3K |
| 97116 | <1% | 1,245 | $3K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 56 | $3K |
| 87186 | <1% | 1,116 | $3K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 33 | $2K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 15 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 375 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 793 | $2K |
| 85610 | <1% | 1,466 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,585 | $2K |
| 87077 | <1% | 637 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,129 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 590 | $1K |
| 83690 | <1% | 3,992 | $1K | |
| 83605 | <1% | 2,494 | $1K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 34 | $1K |
| 87040 | <1% | 1,568 | $978.20 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 720 | $946.84 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 104 | $941.03 |
| J2704 | Injection, propofol, 10 mg | <1% | 170 | $828.74 |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 459 | $787.43 |
| 85730 | <1% | 976 | $774.32 | |
| 83735 | <1% | 2,891 | $708.68 | |
| 80061 | Lipid panel | <1% | 481 | $528.31 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 385 | $470.19 |
| 87210 | <1% | 275 | $401.50 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 62 | $385.16 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 561 | $331.14 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 612 | $237.38 |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 15 | $200.48 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 931 | $179.88 |
| 01999 | <1% | 502 | $176.23 | |
| 85379 | <1% | 197 | $149.21 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 373 | $133.13 |
| 93971 | <1% | 18 | $132.70 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 122 | $120.97 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 234 | $95.71 |
| 90715 | <1% | 66 | $64.67 | |
| 82077 | <1% | 185 | $39.50 | |
| 0002A | <1% | 18 | $31.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 743 | $23.06 |
| 87641 | <1% | 51 | $12.46 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 147 | $5.08 |
| 0001A | <1% | 17 | $1.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 108 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 92 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 475 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 33 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 217 | $0.00 |
| 82550 | 0% | 98 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 90 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 99 | $0.00 |
| 88342 | 0% | 14 | $0.00 | |
| 87081 | 0% | 35 | $0.00 | |
| 86140 | 0% | 14 | $0.00 | |
| 85027 | 0% | 78 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 16 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 63 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 13 | $0.00 |
| 84100 | 0% | 260 | $0.00 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | 0% | 36 | $0.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 127 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 13 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 19 | $0.00 |
| 73110 | 0% | 19 | $0.00 | |
| 10060 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCRUNK, DANIEL (CFO)
| Provider | Location | Paid |
|---|---|---|
| Florida Hospital Zephyrhills INC | Zephyrhills, FL | $9.95M |
| Florida Hospital Dade City INC | Dade City, FL | $5.50M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.